Bookmark and Share
BioAssay: AID 504526

A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (6)

Assay Rationale and Summary: Currently, there are no commercially available vaccines to protect humans against Respiratory syncytial virus (RSV). RSV is associated with substantial morbidity and mortality and is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age. Nevertheless, severe lower respiratory tract disease may occur at any age, more ..
_
   
 Tested Compounds
 Tested Compounds
All(24)
 
 
Active(9)
 
 
Inactive(15)
 
 
 Tested Substances
 Tested Substances
All(25)
 
 
Active(10)
 
 
Inactive(15)
 
 
 Related BioAssays
 Related BioAssays
AID: 504526
Data Source: Southern Research Specialized Biocontainment Screening Center (RSV_DR6)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2011-03-22
Hold-until Date: 2012-03-18
Modify Date: 2012-03-20

Data Table ( Complete ):           Active    All
BioActive Compounds: 9
Depositor Specified Assays
Show more
AIDNameTypeProbeComment
2391A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV)confirmatory Primary and confirmatory screen.
2410An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV)confirmatory Cytotoxicity of primary screen hits.
449732A Titer Reduction Assay to evaluate Selected Compounds as new Inhibitors of Respiratory Syncytial Virus (RSV)other TCID50 on selected compounds.
488972A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using purified and synthesized compoundsconfirmatory Confirmatory screen (2) on purified and synthesized compounds.
488976An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using purified and synethesized compoundsconfirmatory Cytotoxicity screen (2) on purified and synthesized compounds.
2440A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory Syncytial Virus (RSV) - Summarysummary Summary AID.
492966A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (3)confirmatory Confirmatory screen (3) on purified and synthesized compounds.
492968An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (3)confirmatory Cytotoxicity screen (3) on purified and synthesized compounds.
493016A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (4)confirmatory Confirmatory screen (4) on purified and synthesized compounds.
493015An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (4)confirmatory Cytotoxicity screen (4) on purified and synthesized compounds.
493088A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (5)confirmatory Confirmatory screen (5) on purified and synthesized compounds.
493090An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (5)confirmatory Cytotoxicity screen (5) on purified and synthesized compounds.
504818An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (8)confirmatory
504825An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (10)confirmatory
540337A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (12)confirmatory
588454An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (13)confirmatory
588483An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (14)confirmatory
504823A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (9)confirmatory
504826An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (9)confirmatory
540320A Plaque Reduction Assay to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) (3)other
588485A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (14)confirmatory
602159A Time of Addition Assay to evaluate New Inhibitors of Respiratory syncytial virus (RSV) (2)other1
588455A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (13)confirmatory
504827A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (10)confirmatory
504830A Plaque Reduction Assay to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV)other
540266An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (11)confirmatory
504820A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (8)confirmatory
588791A Plaque Reduction Assay to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) (5)other
504674An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (7)confirmatory
540264A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (11)confirmatory
588713A Plaque Reduction Assay to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) (4)other
504655A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV) using synthesized compounds (7)confirmatory
504829A Time of Addition Assay to evaluate New Inhibitors of Respiratory syncytial virus (RSV)other1
540338An HTS Cytotoxicity Screen to evaluate New Inhibitors of Respiratory Syncytial Virus (RSV) using synethesized compounds (12)confirmatory
Description:
Southern Research's Specialized Biocontainment Screening Center (SRSBSC)
Southern Research Institute (Birmingham, Alabama)
NIH Molecular Libraries Probe Centers Network (MLPCN)
Assay Provider: Dr. William Severson, Southern Research Institute
Grant number: 1 R03 MH082403-01A1

Assay Rationale and Summary: Currently, there are no commercially available vaccines to protect humans against Respiratory syncytial virus (RSV). RSV is associated with substantial morbidity and mortality and is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age. Nevertheless, severe lower respiratory tract disease may occur at any age, especially among the elderly or among those with compromised cardiac, pulmonary, or immune systems. The existing therapies for the acute infection are ribavirin and the prophylactic humanized monoclonal antibody (Synagis from MedImmune) that is limited to use in high risk pediatric patients. The economic impact of RSV infections due to hospitalizations and indirect medical costs is greater than $ 650 million annually. The assay provider has developed and validated an HTS assay that measures cytopathic effect (CPE) induced in HEp-2 cells by RSV infection, using a luminescent-based detection system for signal endpoint. We anticipate that the proposed studies utilizing the Molecular Libraries Probes Production Network (MLPCN) HTS resources will generate multiple scaffolds targeting various junctures in the RSV viral lifecycle. These may be furthered developed into probes to construct novel single or combination therapeutics.
Protocol
Cell Culture: HEp-2 cells (ATCC CCL-23, American Tissue Culture Type) were maintained as adherent cell lines in Optimem 1 with 2 mM L-glutamine and 10% fetal bovine serum (FBS) at 37oC in a humidified 5% CO2 atmosphere. Cells were passaged as needed and harvested from flasks using 0.05% trypsin-EDTA.

Assay Media - Preparation of Complete DMEM/F12: 50 mL Pen/Strep/Glutamine (Gibco, Cat. No. 10378) was added to four liters of room temperature DMEM/F12 (Sigma, Cat. No. D6434) and the pH adjusted to 7.5 using 1N NaOH. The medium was sterile filtered through a 0.2 um filter and 10 mL of HI-FBS was added per 500 mL of media.

RSV culture: Human respiratory syncytial virus (HRSV) strain Long (ATCC VR-26) was used for screening. The RSV stock was prepared in HEp-2 cells using an initial stock obtained from ATCC. Briefly, HEp-2 cells were grown in two T-175 flasks to 50% confluence in Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (CDMEM/F12), pH 7.5 with 2.5 mM L-glutamine, 2% FBS and 125 U of penicillin, 125 ug of streptomycin per ml. 0.2 ml of RSV was added to 25 ml of CDMEM/F12. After three days incubation at 37 degrees C, 5% C02 and high humidity, the supernatant was harvested and the cell debris pelleted by centrifuging at 1,000 rpm for 5 minutes at 18 degrees C. Trehalose and FBS were added to a final concentration of 10% each and the supernatant was aliquoted (1 ml per tube) fast freeze using 100% Ethanol dry ice for five minutes and stored at -80 degrees C. These virus stocks were titrated in HEp-2 cells using an agarose overlay plaque method and the titer was 6.0E+07 pfu/ml.

Dose Response Compound Preparation: For dose response screening, compounds or carrier control (DMSO) were diluted to 6x in Complete DMEM/F12. Test compounds were serially diluted 1:2 resulting in an 8 point dose response dilution series. (final plate well concentration ranging from 50 uM to 0.39 uM and a final DMSO concentration of 0.5%). Twenty ul of each dilution was dispensed to assay plates (3% DMSO) in triplicate.
Control Drug: The positive control drug for this assay, ribavirin [1] (No. 196066, MP Biomedicals, Solon, OH) was solubilized in DMSO. It was diluted and added to the assay plates as described for test compounds. Final concentration for ribavirin was 100uM. All wells contained 0.5% DMSO.

Preparation of HEp-2 cells: Cells were harvested and resuspended to 178,000 cells per ml in Complete DMEM/F12.

Assay Set up: Sixty ul of HEp-2 cells (10,595 cells/well) forty ul of media and 20 ul of 3% DMSO were plated in the cell control wells. Sixty ul of HEp-2 cells (10,595 cells/well), forty ul of a 1:500 dilution of virus (viral MOI = 0.45) and 20 ul of compound or ribavirin control drug were added to the virus control and compound wells. All cell plating was conducted using a Matrix WellMate and cells were maintained at room temperature with stirring during the plating process. The assay plates were incubated for six days at 37 degrees C, 5% CO2 and 90% relative humidity.

Data Analysis: Eight control wells containing cells only and four wells containing cells and virus were included on each assay plate and used to calculate Z' value for each plate and to normalize the data on a per plate basis. Results are reported as percent (%) CPE inhibition and were calculated using the following formula: % CPE inhibition = 100*(Test Cmpd - Med Virus)/(Med Cells - Med Virus). Four ribavirin positive control wells were included on each plate for quality control purposes. To quantify the viral cytopathic effect, IC50s were calculated for each substance using the 4 parameter Levenburg-Marquardt algorithm with the minimum and maximum parameters locked at 0 and 100, respectively.
Comment
Possible artifacts in this assay include, but are not limited to, compounds that interfere with the luciferase reaction, absorb luminescence, or precipitate.

Compounds that demonstrated at least 50% inhibition and were considered active.

The following tiered system has been implemented at Southern Research Institute for use with the PubChem Score. Compounds in the primary screen are scored on a scale of 0-40 based on inhibitory activity where a score of 40 corresponds to 100% inhibition. In the initial confirmatory dose response screen, active compounds were scored on a scale of 41-80 based on the IC50 result while compounds that did not confirm as actives were given the score of 0. In assays using purified and synthesized compounds a scale of 81-100 based on the IC50 result is used to denote a high level of confidence in both the substance and the data. Compounds that did not confirm activity were given the score of 0.
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1IC50 ModifierString
2IC50*FloatμM
3% CPE Inhibition @ 50 uM (50μM**)Inhibition of cytopathic effect of virus at 50 uMFloat%
4% CPE Inhibition @ 25 uM (25μM**)Inhibition of cytopathic effect of virus at 25 uMFloat%
5% CPE Inhibition @ 12.5 uM (12.5μM**)Inhibition of cytopathic effect of virus at 12.50 uMFloat%
6% CPE Inhibition @ 6.25 uM (6.25μM**)Inhibition of cytopathic effect of virus at 6.25 uMFloat%
7% CPE Inhibition @ 3.125 uM (3.125μM**)Inhibition of cytopathic effect of virus at 3.125 uMFloat%
8% CPE Inhibition @ 1.563 uM (1.563μM**)Inhibition of cytopathic effect of virus at 1.563 uMFloat%
9% CPE Inhibition @ 0.781 uM (0.781μM**)Inhibition of cytopathic effect of virus at 0.781 uMFloat%
10% CPE Inhibition @ 0.391 uM (0.391μM**)Inhibition of cytopathic effect of virus at 0.391 uMFloat%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1R03 MH084847-01

Data Table (Concise)
PageFrom: